abstract |
The present invention relates to vaccines containing a polypeptide or protein selected from the group consisting of Leishmania major p54, Q4Q8Z6, Q4Q6T9, Q4QHT2, E9AE98, or an immunologically effective fragment thereof, for use in the prevention or treatment of leishmaniasis. The invention further relates to a pharmaceutical composition comprising such a vaccine. |